

# Internationales 6. Symposium URO ONKO LOGIE

SAVE  
THE  
DATE

20  
23

08. – 09.12.23  
Pullman Köln

www.isuo.eu



## PROGRAMM

### FRIDAY, 08. DECEMBER 2023

**09.00 Welcome** Axel Heidenreich, Köln, DE

#### **09.10 Prostate Cancer 1** **Early detection and management of organ confined prostate cancer**

Moderation: Axel Heidenreich, Cologne, GER; Jörn Witt, Düsseldorf, GER

**09.10** concepts of individual early detection  
Jan Radtke, Düsseldorf, GER

**09.22** which imaging modality is best for early detection?  
Antti Rannikko, Helsinki, FIN

**09.34** 10 debunked myths about prostate cancer  
Scott Eggener, Chicago, USA

#### **09.46 Discussion**

**09.56 Organ confined prostate cancer**  
Still too much surgery for low risk disease  
Axel Heidenreich, Cologne, GER

**10.15** Aktive Surveillance: Integration of WHO group 2  
Scott Eggener, Chicago, US

**10.30** Pro and Contra:  
**10.30 Case Presentation: Christina Steinbach, Cologne, GER**

**10.32** HIFU-Hemiablation is treatment of choice  
Dabiel Eberli, Zürich, SUI

**10.41** radical prostatectomy remains No 1  
Jeff Karnes, Rochester, US

#### **10.50 Discussion**

**11.00 Satellite Symposium 1 | AstraZeneca GmbH**

**11.45** COFFEE BREAK

#### **12.30 non muscle invasive bladder cancer** Moderation: Maximilian Burger, Regensburg, GER; Florian Roghmann, Herne, GER

**12.30** new risk classification of intermediate risk bladder cancer  
Mauricio Brausi, Modena, IT

**12.42** Do we really need fluorescence cystoscopy?  
Martin Kriegmair, München, GER

**12.54** Pro and Contra: management of CG-refraktory bladder cancer  
**Case presentation:** Jakob Musil, Magdeburg

**12.56** Pro radical cystectomy  
Mauricio Brausi, Modena, IT

**13.06** Pro new intravesical and systemic treatment options  
Florian Roghmann, Herne, GER

#### **13.16 Diskussion**

**13.21 Muskel invasive bladder cancer**  
Role of microbiom for response to systemic chemotherapy  
Pia Paffenholz, Cologne, GER

**13.36** Pro and Contra: TURB is superfluous!!

**13.36** TURB remains Standard  
Maximilian Burger, Regensburg, GER

**13.46** mpMRT is safe enough  
Jürgen Fütterer, Nijmegen, NL

#### **13.55 Diskussion**

#### **14.05 SEMI-LIVE Surgery: New surgical methods for urothelial cancer** Moderation: Mauricio Brausi, Modena, I; Christian Bach, Cologne, GER

**14.05** En-Bloc cystectomy and Lymphadenectomy  
Eirik Kjobli, Trondheim, NOR

**14.15** prostate sparing radical cystectomy  
Pfister, Heidenreich, Cologne, GER

**14.25** Ileocoecal-Pouches with umbilical stoma  
Tilman Kälble, Fulda, GER

Organ sparing approach for UUTUC  
Uwe-Bernd Liehr, Magdeburg, GER

#### **14.35 Diskussion**

**14.45** „Why the Y? Humangenetik als Schlüssel in der Uroonkologie“  
Martin Zenker, Magdeburg, GER

**14.55** COFFEE BREAK

**15:25 Satellitensymposium 2 | Novartis Radiopharmaceuticals GmbH**

#### **16.10 prostate cancer 2:** **locally advanced prostate cancer** Moderation: Martin Schostak, Magdeburg; Jeff Karnes, Rochester, USA

**16.10** Pro and Contra: pLAD is superfluous  
**Case presentation** Dr. Constantin Rieger, Köln, GER

**16.12** Pro PSMA  
Christian Gratzke, Freiburg, GER

**16.22** Contra and Pro epLAND  
Jeff Karnes, Rochester, USA

**16.32** pN1: what to do?  
Isabel Heidegger, Innsbruck, AU

**16.47** Pro and Contra: ligometastatic HSPC with bone metastases  
**Case presentation:** Florian Wallstab, Magdeburg, GER

**16.49** SBRT is the way to go  
Alexandros Papachristofilou, Basel, SUI

**16.59** ADT (±RT) remains the best option  
Gunhild von Amsberg, Hamburg, GER

#### **17.09 Diskussion**

#### **17.20 prostate cancer 3: metastatic HSPC and CRPC** Moderation: Isabel Heidegger, Innsbruck, AU; David Pfister, Cologne, GER

**17.20** role of bicalutamide and intermittent ADT 2023  
Martin Schostak, Magdeburg, GER

**17.32** Molecular Analysis: who, when and which panel?  
Anders Bjartell, Lund, SE

**17.44** 177Lu-PSMA Therapy: when and who?  
Ken Herrmann, Essen, GER

**17.56** current algorithm of sequential therapy  
Aurelius Omlin, Zürich, SUI

#### **18.08 Diskussion**

**18.15** End of day 1

## PROGRAMM

### SATURDAY, 9. DECEMBER 2023

**8.30 Welcome**  
Axel Heidenreich, Cologne, GER

#### **8.35 urothelial carcinoma of the upper urinary tract** Moderation: Oliver Hakenberg, Rostock, GER; Friedemann Zengerling, Ulm, GER Locally advanced urothelial carcinoma of the renal pelvis **Case presentation** Dr. Felix Seelemeyer, Cologne, GER

**8.35** role of systemic therapy  
Anja Lorch, Zürich, SUI

**8.47** Pro and Contra: distal ureteral tumor – what to do?  
**Case presentation:** Johanna Vogt, Magdeburg, GER

**8.49** radical nephroureterectomy and Lymphadenectomy  
Vsevolod Matveev, Moskau, RUS

**8.56** kidney preserving surgery  
Joost Boormans, Rotterdam, NL

#### **9.03 Diskussion**

**9.13 Renal Cell Carcinoma**  
Moderation: Axel Heidenreich, Köln; Jens Bedke, Stuttgart, GER

**9.13** State-of -the ART: contrast enhanced CT despite renal insufficiency  
Thomas Benzinger, Cologne, GER

**9.28** focal brachytherapy in the management of renal cancer  
Maciej Pech, Magdeburg, GER

Pro and Contra: organ sparing surgery is the standard approach for cT2 RCC

**9.43 Case presentation:** Resident Magdeburg

**9.45** Pro  
David Pfister, Cologne, GER

**9.52** Contra  
Friedemann Zengerling, Ulm, GER

#### **10.00 Diskussion**

**10.10 Satellite Symposium 3 | MSD SHARP & DOHME GmbH**

**10.55** COFFEE BREAK

#### **11.25 locally advanced renal cell carcinoma** **11.25** is locoregional lymphadenectomy the new standard at radical nephrectomy prior to adjuvant immunooncological therapy? Angelika Borkowetz, Dresden, GER

**11.37** residual tumor resection following immune oncological treatment  
Jens Bedke, Stuttgart, GER

#### **11.49 Diskussion**

#### **12.00 Testis Cancer/penile cancer** Moderation: Angelika Borkowetz, Dresden, GER; Mark Schrader, Berlin, GER

**12.00** organ sparing surgery of penile cancer: surgical technique and results  
Oliver Hakenberg, Rostock, GER

**12.15** Is there a benefit of secondary opinion centres?  
Mark Schrader, Berlin, GER

**12.27** Treatment options of clinical stage IIA/B NSGCT  
Axel Heidenreich, Cologne, GER

#### **12.39 Diskussion**

**12.50 Satellite Symposium 4 | Astellas Pharma GmbH**

**13.35 Adjourn and outlook for 2025**  
Martin Schostak, Magdeburg, GER

## Dear Colleagues and Friends,

It is our pleasure to invite you to the 6th International Symposium on the management of urogenital malignancies to be held from December 8 to 9, 2023 in Cologne, Germany.

It is the purpose of our scientific meeting to provide you with information on the latest developments of 2023 with regard to the diagnosis, conservative and surgical treatment of malignant tumors of the upper and lower urogenital tract. As in recent years, interdisciplinary case discussions, Pro- and Con debates, state-of-the-art lectures and semi-live videos will be presented by well-known national and international speakers.

We have selected all those innovations around uro-oncological surgery, radiation therapy and system treatment which will have the most pronounced effects on the management of our patients and which should be introduced in daily clinical routine immediately.

The symposium is organized as a hybrid meeting with simultaneous translation so that no information will get lost and so that all of you can participate in the interactive discussions. Later on you might follow the presentations on demand repetitively.

We are looking forward to welcoming you personally and we are looking forward to fruitful discussions in the surrounding and stimulating atmosphere of Cologne at Christmas time

We remain with warmest regards,  
Sincerely yours,

**Prof. Dr. med. Dr. h.c.  
Axel Heidenreich**

*Director of the Department of Urology, Uro-Oncology, and Special Urological and Robot-Assisted Surgery,  
University Hospital Cologne*

**Prof. Dr. med.  
Martin Schostak**

*Department of Urology, Uro-Oncology,  
Robot-Assisted and Focal Therapy,  
University Hospital, Otto-von-Guericke-  
University, Magdeburg, Germany*

## GENERAL INFORMATION

## ORGANIZER

**INTERCOM Dresden GmbH** | Zellescher Weg 3 | 01069 Dresden  
in cooperation with the scientific direction of

**Prof. Dr. med. Dr. h.c Axel Heidenreich**

*Director of the Department of Urology, Uro-Oncology, and Special Urological and Robot-Assisted Surgery, University Hospital Cologne*

**Prof. Dr. med. Martin Schostak**

*Department of Urology, Uro-Oncology, Robot-Assisted and Focal Therapy,  
University Hospital, Otto-von-Guericke-University, Magdeburg, Germany*

## EVENT LOCATION

Pullman Köln

Helenenstraße 14 | 50667 Köln

## PARTICIPATION FEE

Attendance at the event	early bird	regular
Specialist physician	285,00 €	305,00 €
Junior physician	160,00 €	190,00 €
Student	Free of charge (with verification)	
University hospital employee (Urology) Cologne and Magdeburg	Free of charge (with verification)	

Virtual	early bird	regular
Specialist physician	175,00 €	205,00 €
Junior physician	105,00€	125,00 €
Student	Free of charge (with verification)	
University hospital employee (Urology) Cologne and Magdeburg	Free of charge (with verification)	

## REGISTRATION AT

[www.isuo.eu/2023/anmeldung](http://www.isuo.eu/2023/anmeldung)

early bird: until 30. Sep. 2023

**CME** Continuing education credits are applied for at the responsible state medical association.

## ORGANISATION | INDUSTRIAL EXHIBITION INTERCOM

**INTERCOM Dresden GmbH** | Christian Nitzsche, Katharina Henze  
Zellescher Weg 3, 01069 Dresden | **Telefon:** +49 351 320173-30, -70  
**E-Mail:** [isuo@intercom.de](mailto:isuo@intercom.de)

\*INTERCOM Dresden GmbH is the organizer. All registration fees are per person, including 19% VAT, collected in the name and for the account of INTERCOM Dresden GmbH, Zellescher Weg 3, 01069 Dresden, Germany, UST-ID Nr.: DE 186530195 | This event is supported by industry sponsorship. This sponsorship will be used exclusively for the financing of the following conference services: Participant administration, organisational costs, speaker's fee, printed material, rental costs for event rooms, rental costs for presentation technology as well as for appropriate refreshments during breaks.

## MAIN TOPICS

## Prostate Cancer:

active surveillance, innovative treatment options in organ confined and locally advanced prostate cancer, radionuclid and targeted treatment options

## Urothelial Cancer:

immuno-oncological treatment concepts, role of radical cystectomy in the management of muscle invasive disease, SEMI LIVE surgery on urinary diversions, management of upper urinary tract cancer

## Renal Cancer:

organ preserving surgical and non-surgical treatment options, cytoreductive nephrectomy, retroperitoneal lymph node dissection

## Testis Cancer/Penile Cancer:

state-of-the Art guidelines recommended treatment options

**INTERCOM**  
DIE VERANSTALTUNGSAGENTUR

in Zusammenarbeit mit den wissenschaftlichen Partnern /  
in cooperation with the scientific partners



## SPONSORS

## Platinum sponsors

	<b>Astellas Pharma GmbH, München</b> Sponsoringpaket Platin und Firmensymposium 20.000 €
	<b>AstraZeneca GmbH, Hamburg</b> Sponsoringpaket Platin und Firmensymposium 20.000 € (vorbehaltlich interner Genehmigung)

	<b>Janssen, Neuss</b> Sponsoringpaket Platin 10.000,00 €
--	---

	<b>MSD SHARP &amp; DOHME GMBH, München</b> Sponsoringpaket Platin und Firmensymposium 20.000,00 €
--	---

	<b>Novartis Radiopharmaceuticals GmbH, Nürnberg</b> Sponsoringpaket Platin und Firmensymposium 20.000 €
--	---

## Silver sponsors

	<b>Aristo Pharma GmbH, Berlin</b> Sponsoringpaket Silber 6.000,00 €
--	---

	<b>Bayer Vital GmbH, Leverkusen</b> Sponsoringpaket Silber 6.000,00 €
--	---

	<b>Bristol Myers Squibb GmbH &amp; Co KGaA, München</b> Sponsoringpaket Silber 6.000 €
--	--

	<b>Merck Healthcare Germany GmbH, Weiterstadt</b> Sponsoringpaket Silber 6.000,00 €
--	---

## Bronze sponsors

	<b>bk medical GmbH, Quickborn</b>
--	-----------------------------------

	<b>EDAP TMS GmbH, Flensburg</b>
--	---------------------------------

	<b>Farco-Pharma GmbH, Köln</b> Sponsoringpaket Bronze 3.000 €
--	--

	<b>medac GmbH, Wedel</b>
--	--------------------------

Gemäß dem FSA-Kodex (Umsetzung § 20 Abs. 5 FSA-Kodex Fachkreise) und den Richtlinien des AKG (Arzneimittel und Kooperation im Gesundheitswesen e.V.) wird auf Wunsch der o. g. Firmen über die finanzielle Unterstützung zu diesem Symposium informiert. Die Angaben verstehen sich zzgl. der gesetzlichen Mehrwertsteuer. Stand 31.08.2023

## Ihre Ansprechpartner:

**INTERCOM Dresden GmbH** | Christian Nitzsche, Katharina Henze  
Zellescher Weg 3, 01069 Dresden | **Telefon:** +49 351 320173-30, -70  
**E-Mail:** [isuo@intercom.de](mailto:isuo@intercom.de)